Callizot N - Search Results

1

Late onset neurological phenotype of the X-ALD gene inactivation in mice: a mouse model for adrenomyeloneuropathy.

Pujol A, Hindelang C, Callizot N, Bartsch U, Schachner M, Mandel JL. Pujol A, et al. Among authors: callizot n. Hum Mol Genet. 2002 Mar 1;11(5):499-505. doi: 10.1093/hmg/11.5.499. Hum Mol Genet. 2002. PMID: 11875044

2

Functional overlap between ABCD1 (ALD) and ABCD2 (ALDR) transporters: a therapeutic target for X-adrenoleukodystrophy.

Pujol A, Ferrer I, Camps C, Metzger E, Hindelang C, Callizot N, Ruiz M, Pàmpols T, Giròs M, Mandel JL. Pujol A, et al. Among authors: callizot n. Hum Mol Genet. 2004 Dec 1;13(23):2997-3006. doi: 10.1093/hmg/ddh323. Epub 2004 Oct 15. Hum Mol Genet. 2004. PMID: 15489218

3

The frissonnant mutant mouse, a model of dopamino-sensitive, inherited motor syndrome.

Callizot N, Guénet JL, Baillet C, Warter JM, Poindron P. Callizot N, et al. Neurobiol Dis. 2001 Jun;8(3):447-58. doi: 10.1006/nbdi.2001.0393. Neurobiol Dis. 2001. PMID: 11442353

4

Interleukin-6 attenuates the development of experimental diabetes-related neuropathy.

Andriambeloson E, Baillet C, Vitte PA, Garotta G, Dreano M, Callizot N. Andriambeloson E, et al. Among authors: callizot n. Neuropathology. 2006 Feb;26(1):32-42. doi: 10.1111/j.1440-1789.2006.00651.x. Neuropathology. 2006. PMID: 16521477

5

Interleukin-6 protects against paclitaxel, cisplatin and vincristine-induced neuropathies without impairing chemotherapeutic activity.

Callizot N, Andriambeloson E, Glass J, Revel M, Ferro P, Cirillo R, Vitte PA, Dreano M. Callizot N, et al. Cancer Chemother Pharmacol. 2008 Nov;62(6):995-1007. doi: 10.1007/s00280-008-0689-7. Epub 2008 Feb 13. Cancer Chemother Pharmacol. 2008. PMID: 18270703

6

Pyridoxine-induced neuropathy in rats: a sensory neuropathy that responds to 4-methylcatechol.

Callizot N, Warter JM, Poindron P. Callizot N, et al. Neurobiol Dis. 2001 Aug;8(4):626-35. doi: 10.1006/nbdi.2001.0408. Neurobiol Dis. 2001. PMID: 11493027

7

A new long term in vitro model of myelination.

Callizot N, Combes M, Steinschneider R, Poindron P. Callizot N, et al. Exp Cell Res. 2011 Oct 1;317(16):2374-83. doi: 10.1016/j.yexcr.2011.07.002. Epub 2011 Jul 12. Exp Cell Res. 2011. PMID: 21777582

8

Glutamate protects neuromuscular junctions from deleterious effects of β-amyloid peptide and conversely: an in vitro study in a nerve-muscle coculture.

Combes M, Poindron P, Callizot N. Combes M, et al. Among authors: callizot n. J Neurosci Res. 2015 Apr;93(4):633-43. doi: 10.1002/jnr.23524. Epub 2014 Dec 9. J Neurosci Res. 2015. PMID: 25491262

9

Operational dissection of β-amyloid cytopathic effects on cultured neurons.

Callizot N, Combes M, Steinschneider R, Poindron P. Callizot N, et al. J Neurosci Res. 2013 May;91(5):706-16. doi: 10.1002/jnr.23193. Epub 2013 Feb 13. J Neurosci Res. 2013. PMID: 23404368

10

Necrosis, apoptosis, necroptosis, three modes of action of dopaminergic neuron neurotoxins.

Callizot N, Combes M, Henriques A, Poindron P. Callizot N, et al. PLoS One. 2019 Apr 25;14(4):e0215277. doi: 10.1371/journal.pone.0215277. eCollection 2019. PLoS One. 2019. PMID: 31022188 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

39 results

Search Page

Filters